Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
The Unique Combination of Multi-dimensional Genomics & AI in Cancer Care
Detection
Early cancer detection by screening for tumor DNA in the blood (ctDNA).
Profiling
Next-generation sequencing (NGS) tumor profiling for precision therapies.
Monitoring
Personalized ctDNA monitoring for recurrence risk and treatment responses.
Innovation
Discovery of multi-omics targets for new drug insights and novel therapies development.
News & Updates
Get the latest news and updates of our company and medical field.
From Recurrence to Resistance: Real-World Performance of a Hybrid ctDNA Assay in Breast Cancer Management
Penang, Malaysia – At the 14th Asia-Pacific Breast Cancer Summit (APBCS) 2026, Gene Solutions presented real-world data on K-TRACK, a novel hybrid circulating tumor DNA (ctDNA) testing approach. This integrative
From Basic Testing to an AI-Powered Comprehensive NIPT Ecosystem: Shaping the Future of Prenatal Care in India
NEW DELHI, INDIA — At the 68th All India Congress of Obstetricians and Gynecologists (AICOG 2026), Gene Solutions India hosted an industry session titled “Comprehensive Prenatal Screening for Better Maternal–Fetal Outcomes.” The session brought together
K-CONNECT SUMMIT 2026: Advancing AI, Multi-Omics, and Precision Oncology Across Asia-Pacific
K-CONNECT SUMMIT 2026, co-hosted by Gene Solutions, the Vietnam Institute of Clinical Medicine and Pharmacy, and the Vietnam Medical Association, will convene oncologists, healthcare professionals, researchers, and international experts to advance scientific exchange in early
Gene Solutions Introduces Dual Tumor-Blood Liquid Biopsy Comprehensive Profiling Upgrades for K-TRACK and K-4CARE
Deeper molecular insights, with faster turn-around time, for sooner decisions across the patient journey Singapore, 30 April 2026 — Gene Solutions has announced major upgrades to their K-TRACK and K-4CARE portfolios,
Gene Solutions is accelerating access to advanced genetic testing in India through its strategic collaboration with Genique Lifesciences
We’re pleased to share that, through our strategic collaboration with Genique Lifesciences, we are expanding access to advanced AI-enabled genomic testing in India — bringing genomic insights closer to clinical practice
Gene Solutions Expands SPOT-MAS Portfolio with Accessible Cancer Screening and Precision Triage Solutions
April 20, 2026 — Gene Solutions announced the expansion of its SPOT‑MAS portfolio with two new solutions: SPOT-MAS CRC and SPOT-MAS Eva. These additions bring accessible blood-based colorectal cancer screening and
triSure NIPT Debuts in Taiwan, Expanding Non-Invasive Prenatal Screening Beyond Aneuploidy
All-in-one approach integrates chromosomal analysis, single-gene disorder screening, and maternal carrier screening from a single blood draw. TAIPEI, April 14, 2026 /PRNewswire/ — At the prestigious Taiwan Association of Obstetrics and Gynecology (TAOG)
Building Momentum in Precision Oncology Across Latin America
At the 1st Symposium on Genomics and Precision Oncology in Brazil (April 10–11), over 300 oncologists gathered to advance the future of cancer care and the Gene Solutions Brazil team
Who May Consider MCED Testing?
Multi-Cancer Early Detection (MCED) testing is an emerging approach that aims to identify signals associated with multiple cancers through a single blood sample. As awareness of MCED grows, some individuals
Elevating Multi-Cancer Early Detection Through Genomic Innovation
On 7 February 2026, the Gene Solutions Hong Kong team co-organized a public health talk in Hong Kong that brought together 40+ participants—including patients’ families and health‑conscious individuals—to address a
Gene Solutions & ATC introducing Oncology Portfolio in Türkiye at the 2nd International Hereditary Cancers Congress with Industry Symposium & Oral Presentation
At the 2nd International Hereditary Cancers Congress (IHCC) held in Antalya, Türkiye (February 5–8, 2026), Gene Solutions – co-hosted with its Türkiye’s distribution partner – ATC – organized a dedicated
Cost & Insurance Coverage for MCED Tests in Singapore
This article is for educational purposes only. It does not provide specific pricing, promotions, or purchasing recommendations. Instead, it explains the general cost structure of ctDNA-based MCED tests and current insurance coverage considerations, including
From Recurrence to Resistance: Real-World Performance of a Hybrid ctDNA Assay in Breast Cancer Management
Penang, Malaysia – At the 14th Asia-Pacific Breast Cancer Summit (APBCS) 2026, Gene Solutions presented real-world data on K-TRACK, a novel hybrid circulating tumor DNA (ctDNA) testing approach. This integrative
From Basic Testing to an AI-Powered Comprehensive NIPT Ecosystem: Shaping the Future of Prenatal Care in India
NEW DELHI, INDIA — At the 68th All India Congress of Obstetricians and Gynecologists (AICOG 2026), Gene Solutions India hosted an industry session titled “Comprehensive Prenatal Screening for Better Maternal–Fetal Outcomes.” The session brought together
K-CONNECT SUMMIT 2026: Advancing AI, Multi-Omics, and Precision Oncology Across Asia-Pacific
K-CONNECT SUMMIT 2026, co-hosted by Gene Solutions, the Vietnam Institute of Clinical Medicine and Pharmacy, and the Vietnam Medical Association, will convene oncologists, healthcare professionals, researchers, and international experts to advance scientific exchange in early
Gene Solutions Introduces Dual Tumor-Blood Liquid Biopsy Comprehensive Profiling Upgrades for K-TRACK and K-4CARE
Deeper molecular insights, with faster turn-around time, for sooner decisions across the patient journey Singapore, 30 April 2026 — Gene Solutions has announced major upgrades to their K-TRACK and K-4CARE portfolios,
Gene Solutions is accelerating access to advanced genetic testing in India through its strategic collaboration with Genique Lifesciences
We’re pleased to share that, through our strategic collaboration with Genique Lifesciences, we are expanding access to advanced AI-enabled genomic testing in India — bringing genomic insights closer to clinical practice
Gene Solutions Expands SPOT-MAS Portfolio with Accessible Cancer Screening and Precision Triage Solutions
April 20, 2026 — Gene Solutions announced the expansion of its SPOT‑MAS portfolio with two new solutions: SPOT-MAS CRC and SPOT-MAS Eva. These additions bring accessible blood-based colorectal cancer screening and
triSure NIPT Debuts in Taiwan, Expanding Non-Invasive Prenatal Screening Beyond Aneuploidy
All-in-one approach integrates chromosomal analysis, single-gene disorder screening, and maternal carrier screening from a single blood draw. TAIPEI, April 14, 2026 /PRNewswire/ — At the prestigious Taiwan Association of Obstetrics and Gynecology (TAOG)
Building Momentum in Precision Oncology Across Latin America
At the 1st Symposium on Genomics and Precision Oncology in Brazil (April 10–11), over 300 oncologists gathered to advance the future of cancer care and the Gene Solutions Brazil team
Who May Consider MCED Testing?
Multi-Cancer Early Detection (MCED) testing is an emerging approach that aims to identify signals associated with multiple cancers through a single blood sample. As awareness of MCED grows, some individuals
Elevating Multi-Cancer Early Detection Through Genomic Innovation
On 7 February 2026, the Gene Solutions Hong Kong team co-organized a public health talk in Hong Kong that brought together 40+ participants—including patients’ families and health‑conscious individuals—to address a
Gene Solutions & ATC introducing Oncology Portfolio in Türkiye at the 2nd International Hereditary Cancers Congress with Industry Symposium & Oral Presentation
At the 2nd International Hereditary Cancers Congress (IHCC) held in Antalya, Türkiye (February 5–8, 2026), Gene Solutions – co-hosted with its Türkiye’s distribution partner – ATC – organized a dedicated
Cost & Insurance Coverage for MCED Tests in Singapore
This article is for educational purposes only. It does not provide specific pricing, promotions, or purchasing recommendations. Instead, it explains the general cost structure of ctDNA-based MCED tests and current insurance coverage considerations, including
From Recurrence to Resistance: Real-World Performance of a Hybrid ctDNA Assay in Breast Cancer Management
Penang, Malaysia – At the 14th Asia-Pacific Breast Cancer Summit (APBCS) 2026, Gene Solutions presented real-world data on K-TRACK, a novel hybrid circulating tumor DNA (ctDNA) testing approach. This integrative
From Basic Testing to an AI-Powered Comprehensive NIPT Ecosystem: Shaping the Future of Prenatal Care in India
NEW DELHI, INDIA — At the 68th All India Congress of Obstetricians and Gynecologists (AICOG 2026), Gene Solutions India hosted an industry session titled “Comprehensive Prenatal Screening for Better Maternal–Fetal Outcomes.” The session brought together
Who May Consider MCED Testing?
Multi-Cancer Early Detection (MCED) testing is an emerging approach that aims to identify signals associated with multiple cancers through a single blood sample. As awareness of MCED grows, some individuals
Elevating Multi-Cancer Early Detection Through Genomic Innovation
On 7 February 2026, the Gene Solutions Hong Kong team co-organized a public health talk in Hong Kong that brought together 40+ participants—including patients’ families and health‑conscious individuals—to address a
Gene Solutions & ATC introducing Oncology Portfolio in Türkiye at the 2nd International Hereditary Cancers Congress with Industry Symposium & Oral Presentation
At the 2nd International Hereditary Cancers Congress (IHCC) held in Antalya, Türkiye (February 5–8, 2026), Gene Solutions – co-hosted with its Türkiye’s distribution partner – ATC – organized a dedicated
Cost & Insurance Coverage for MCED Tests in Singapore
This article is for educational purposes only. It does not provide specific pricing, promotions, or purchasing recommendations. Instead, it explains the general cost structure of ctDNA-based MCED tests and current insurance coverage considerations, including
From Recurrence to Resistance: Real-World Performance of a Hybrid ctDNA Assay in Breast Cancer Management
Penang, Malaysia – At the 14th Asia-Pacific Breast Cancer Summit (APBCS) 2026, Gene Solutions presented real-world data on K-TRACK, a novel hybrid circulating tumor DNA (ctDNA) testing approach. This integrative
From Basic Testing to an AI-Powered Comprehensive NIPT Ecosystem: Shaping the Future of Prenatal Care in India
NEW DELHI, INDIA — At the 68th All India Congress of Obstetricians and Gynecologists (AICOG 2026), Gene Solutions India hosted an industry session titled “Comprehensive Prenatal Screening for Better Maternal–Fetal Outcomes.” The session brought together
K-CONNECT SUMMIT 2026: Advancing AI, Multi-Omics, and Precision Oncology Across Asia-Pacific
K-CONNECT SUMMIT 2026, co-hosted by Gene Solutions, the Vietnam Institute of Clinical Medicine and Pharmacy, and the Vietnam Medical Association, will convene oncologists, healthcare professionals, researchers, and international experts to advance scientific exchange in early
Gene Solutions Introduces Dual Tumor-Blood Liquid Biopsy Comprehensive Profiling Upgrades for K-TRACK and K-4CARE
Deeper molecular insights, with faster turn-around time, for sooner decisions across the patient journey Singapore, 30 April 2026 — Gene Solutions has announced major upgrades to their K-TRACK and K-4CARE portfolios,
Gene Solutions is accelerating access to advanced genetic testing in India through its strategic collaboration with Genique Lifesciences
We’re pleased to share that, through our strategic collaboration with Genique Lifesciences, we are expanding access to advanced AI-enabled genomic testing in India — bringing genomic insights closer to clinical practice
Gene Solutions Expands SPOT-MAS Portfolio with Accessible Cancer Screening and Precision Triage Solutions
April 20, 2026 — Gene Solutions announced the expansion of its SPOT‑MAS portfolio with two new solutions: SPOT-MAS CRC and SPOT-MAS Eva. These additions bring accessible blood-based colorectal cancer screening and
triSure NIPT Debuts in Taiwan, Expanding Non-Invasive Prenatal Screening Beyond Aneuploidy
All-in-one approach integrates chromosomal analysis, single-gene disorder screening, and maternal carrier screening from a single blood draw. TAIPEI, April 14, 2026 /PRNewswire/ — At the prestigious Taiwan Association of Obstetrics and Gynecology (TAOG)
Building Momentum in Precision Oncology Across Latin America
At the 1st Symposium on Genomics and Precision Oncology in Brazil (April 10–11), over 300 oncologists gathered to advance the future of cancer care and the Gene Solutions Brazil team
Who May Consider MCED Testing?
Multi-Cancer Early Detection (MCED) testing is an emerging approach that aims to identify signals associated with multiple cancers through a single blood sample. As awareness of MCED grows, some individuals
Elevating Multi-Cancer Early Detection Through Genomic Innovation
On 7 February 2026, the Gene Solutions Hong Kong team co-organized a public health talk in Hong Kong that brought together 40+ participants—including patients’ families and health‑conscious individuals—to address a
Gene Solutions & ATC introducing Oncology Portfolio in Türkiye at the 2nd International Hereditary Cancers Congress with Industry Symposium & Oral Presentation
At the 2nd International Hereditary Cancers Congress (IHCC) held in Antalya, Türkiye (February 5–8, 2026), Gene Solutions – co-hosted with its Türkiye’s distribution partner – ATC – organized a dedicated
Cost & Insurance Coverage for MCED Tests in Singapore
This article is for educational purposes only. It does not provide specific pricing, promotions, or purchasing recommendations. Instead, it explains the general cost structure of ctDNA-based MCED tests and current insurance coverage considerations, including
From Recurrence to Resistance: Real-World Performance of a Hybrid ctDNA Assay in Breast Cancer Management
Penang, Malaysia – At the 14th Asia-Pacific Breast Cancer Summit (APBCS) 2026, Gene Solutions presented real-world data on K-TRACK, a novel hybrid circulating tumor DNA (ctDNA) testing approach. This integrative
From Basic Testing to an AI-Powered Comprehensive NIPT Ecosystem: Shaping the Future of Prenatal Care in India
NEW DELHI, INDIA — At the 68th All India Congress of Obstetricians and Gynecologists (AICOG 2026), Gene Solutions India hosted an industry session titled “Comprehensive Prenatal Screening for Better Maternal–Fetal Outcomes.” The session brought together
K-CONNECT SUMMIT 2026: Advancing AI, Multi-Omics, and Precision Oncology Across Asia-Pacific
K-CONNECT SUMMIT 2026, co-hosted by Gene Solutions, the Vietnam Institute of Clinical Medicine and Pharmacy, and the Vietnam Medical Association, will convene oncologists, healthcare professionals, researchers, and international experts to advance scientific exchange in early
Gene Solutions Introduces Dual Tumor-Blood Liquid Biopsy Comprehensive Profiling Upgrades for K-TRACK and K-4CARE
Deeper molecular insights, with faster turn-around time, for sooner decisions across the patient journey Singapore, 30 April 2026 — Gene Solutions has announced major upgrades to their K-TRACK and K-4CARE portfolios,
Gene Solutions is accelerating access to advanced genetic testing in India through its strategic collaboration with Genique Lifesciences
We’re pleased to share that, through our strategic collaboration with Genique Lifesciences, we are expanding access to advanced AI-enabled genomic testing in India — bringing genomic insights closer to clinical practice
Gene Solutions Expands SPOT-MAS Portfolio with Accessible Cancer Screening and Precision Triage Solutions
April 20, 2026 — Gene Solutions announced the expansion of its SPOT‑MAS portfolio with two new solutions: SPOT-MAS CRC and SPOT-MAS Eva. These additions bring accessible blood-based colorectal cancer screening and
triSure NIPT Debuts in Taiwan, Expanding Non-Invasive Prenatal Screening Beyond Aneuploidy
All-in-one approach integrates chromosomal analysis, single-gene disorder screening, and maternal carrier screening from a single blood draw. TAIPEI, April 14, 2026 /PRNewswire/ — At the prestigious Taiwan Association of Obstetrics and Gynecology (TAOG)
Building Momentum in Precision Oncology Across Latin America
At the 1st Symposium on Genomics and Precision Oncology in Brazil (April 10–11), over 300 oncologists gathered to advance the future of cancer care and the Gene Solutions Brazil team
Who May Consider MCED Testing?
Multi-Cancer Early Detection (MCED) testing is an emerging approach that aims to identify signals associated with multiple cancers through a single blood sample. As awareness of MCED grows, some individuals
Elevating Multi-Cancer Early Detection Through Genomic Innovation
On 7 February 2026, the Gene Solutions Hong Kong team co-organized a public health talk in Hong Kong that brought together 40+ participants—including patients’ families and health‑conscious individuals—to address a
Gene Solutions & ATC introducing Oncology Portfolio in Türkiye at the 2nd International Hereditary Cancers Congress with Industry Symposium & Oral Presentation
At the 2nd International Hereditary Cancers Congress (IHCC) held in Antalya, Türkiye (February 5–8, 2026), Gene Solutions – co-hosted with its Türkiye’s distribution partner – ATC – organized a dedicated
Cost & Insurance Coverage for MCED Tests in Singapore
This article is for educational purposes only. It does not provide specific pricing, promotions, or purchasing recommendations. Instead, it explains the general cost structure of ctDNA-based MCED tests and current insurance coverage considerations, including
From Recurrence to Resistance: Real-World Performance of a Hybrid ctDNA Assay in Breast Cancer Management
Penang, Malaysia – At the 14th Asia-Pacific Breast Cancer Summit (APBCS) 2026, Gene Solutions presented real-world data on K-TRACK, a novel hybrid circulating tumor DNA (ctDNA) testing approach. This integrative
From Basic Testing to an AI-Powered Comprehensive NIPT Ecosystem: Shaping the Future of Prenatal Care in India
NEW DELHI, INDIA — At the 68th All India Congress of Obstetricians and Gynecologists (AICOG 2026), Gene Solutions India hosted an industry session titled “Comprehensive Prenatal Screening for Better Maternal–Fetal Outcomes.” The session brought together
CAP-Accredited Laboratory
Within our global network of 14 NGS laboratories, Gene Solutions maintains two facilities with CAP accreditation. This specialization in next-generation sequencing (NGS) demonstrates our commitment to international laboratory benchmarks.
Our adherence to these rigorous standards supports the delivery of reliable genomic testing for patients.
Gene Solutions Laboratories CAP#9709518
